| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – |
| 19 Oct 2026 |
8-K: Termination of a Material Definitive Agreement
As previously disclosed, Collegium Pharmaceutical, Inc. (the “Company”) is party to a License Agreement (U.S.), dated as of January 13, 2015, with Grünenthal GmbH (“Grünenthal”) (as amended, the “Grünenthal License”) which the Company as... |
| 13 Aug 2026 |
8-K: Other Events
On August 12, 2026, Collegium Pharmaceutical, Inc. (“Collegium” or the “Company”) announced the execution of an accelerated share repurchase agreement (the “ASR Agreement”) with Jefferies LLC to repurchase $50 million of the Company’s co... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Completed Acquisition of AZSTARYS®, Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – |
| 15 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 14, 2026, Collegium Pharmaceutical, Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders (the “Annual Meeting”). A total of 32,406,969 shares of common stock of the Company were entitled to vote as of March 31, 2026, ... |
| 12 May 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Departure/Election of Directors or Officers; Compensation +1 more
The name of the plan is the Collegium Pharmaceutical, Inc. 2026 Inducement Plan (the “Plan”). The purpose of the Plan is to enable Collegium Pharmaceutical, Inc. (the “Company”) and its Affiliates to grant equity awards to induce highly-... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – |
| 07 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 6, 2026, the board of directors (“Board”) of Collegium Pharmaceutical, Inc. (the “Company”) approved the nomination of Michael Donovan to stand for election at the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeti... |
| 19 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – |
| 08 Jan 2026 |
8-K: Regulation FD Disclosure
Investor Presentation January 2026 | Nasdaq: COLL Healthier people. Stronger communities. |
| 30 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
– Five-Year Financing with Favorable Terms that Significantly Reduce Interest Rate – |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – |
| 07 Jul 2025 |
8-K: Other Events
On July 1, 2025, the Board of Directors of Collegium Pharmaceutical, Inc. (the “Company”) authorized a new share repurchase program to repurchase up to $150 million of the Company’s shares of common stock through December 31, 2026. The t... |
| 19 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The name of the plan is the Collegium Pharmaceutical, Inc. 2025 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Collegium Pharmaceu... |
| 12 May 2025 |
8-K: Other Events
On May 12, 2025, Collegium Pharmaceutical, Inc. (“Collegium” or the “Company”) announced the execution of an accelerated share repurchase agreement (the “ASR Agreement”) with Jefferies LLC to repurchase $25 million of the Company’s commo... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Generated Q1’25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – |
| 17 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
On March 14, 2025, the board of directors (“Board”) of Collegium Pharmaceutical, Inc. (the “Company”) approved the nomination of Dr. Carlos Paya to stand for election at the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meet... |
| 27 Feb 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
– Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – |
Loading...